Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 11

1.

A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.

Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Dřevínek P, Griese M, McKone EF, Wainwright CE, Konstan MW, Moss R, Ratjen F, Sermet-Gaudelus I, Rowe SM, Dong Q, Rodriguez S, Yen K, Ordoñez C, Elborn JS; VX08-770-102 Study Group.

N Engl J Med. 2011 Nov 3;365(18):1663-72. doi: 10.1056/NEJMoa1105185.

PMID:
22047557
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation.

Sermet-Gaudelus I.

Eur Respir Rev. 2013 Mar 1;22(127):66-71. doi: 10.1183/09059180.00008512. Review.

PMID:
23457167
[PubMed - indexed for MEDLINE]
Free Article
3.

Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.

Pettit RS.

Ann Pharmacother. 2012 Jul-Aug;46(7-8):1065-75. doi: 10.1345/aph.1R076. Epub 2012 Jun 26. Review.

PMID:
22739718
[PubMed - indexed for MEDLINE]
4.

Cystic fibrosis in an era of genomically guided therapy.

Barrett PM, Alagely A, Topol EJ.

Hum Mol Genet. 2012 Oct 15;21(R1):R66-71. Epub 2012 Aug 21. Review. Erratum in: Hum Mol Genet. 2013 May 1;22(9):1911.

PMID:
22914736
[PubMed - indexed for MEDLINE]
Free Article
5.

Targeting a genetic defect: cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis.

Derichs N.

Eur Respir Rev. 2013 Mar 1;22(127):58-65. doi: 10.1183/09059180.00008412. Review.

PMID:
23457166
[PubMed - indexed for MEDLINE]
Free Article
6.

[Cystic fibrosis: new treatments targeting the CFTR protein].

Fajac I, Sermet-Gaudelus I.

Rev Mal Respir. 2013 Apr;30(4):255-61. doi: 10.1016/j.rmr.2012.10.631. Epub 2013 Jan 11. Review. French.

PMID:
23664284
[PubMed - indexed for MEDLINE]
7.

Cystic fibrosis transmembrane conductance regulator dysfunction and its treatment.

Hull J.

J R Soc Med. 2012 Jun;105 Suppl 2:S2-8. doi: 10.1258/jrsm.2012.12s001. Review. No abstract available.

PMID:
22688363
[PubMed - indexed for MEDLINE]
8.

Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease.

Lee TW, Southern KW.

Cochrane Database Syst Rev. 2012 Oct 17;10:CD005599. doi: 10.1002/14651858.CD005599.pub3. Review. Update in: Cochrane Database Syst Rev. 2013;11:CD005599.

PMID:
23076917
[PubMed - indexed for MEDLINE]
9.

Leukotriene receptor antagonists in children with cystic fibrosis lung disease : anti-inflammatory and clinical effects.

Schmitt-Grohé S, Zielen S.

Paediatr Drugs. 2005;7(6):353-63. Review.

PMID:
16356023
[PubMed - indexed for MEDLINE]
10.

Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease.

Lee T, Southern KW.

Cochrane Database Syst Rev. 2007 Apr 18;(2):CD005599. Review. Update in: Cochrane Database Syst Rev. 2012;10:CD005599.

PMID:
17443603
[PubMed - indexed for MEDLINE]
11.

Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.

Keam SJ, Keating GM.

Treat Respir Med. 2004;3(4):247-68. Review.

PMID:
15350163
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk